Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

This drug is again a once-a-week injection that combines the long-acting amylin analogue, cagrilintide, with semaglutide. It works in a similar way to just semaglutide, but may offer better ...

It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel increases in serious and potentially fatal comorbidities, particularly type 2 ...

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and ...

Semaglutide was initially approved under the brand name Ozempic for Type 2 diabetes, while the brand name Wegovy is only approved for weight loss. Here, we’ll compare tirzepatide (Zepbound ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...